A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B

PHASE3CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

October 31, 2014

Conditions
Hemophilia B
Interventions
BIOLOGICAL

rIX-FP

Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)

Trial Locations (17)

2145

The Children's Hospital at Westmead, Westmead

3052

The Royal Children's Hospital, Melbourne, Parkville

13385

Hôpital d'enfants La Timone, Marseille

20122

IRCCS Ospendale Maggiore (Centro emofilia e Trombosi), Milan

28046

H.U. La Paz, Madrid

40225

Universitätsklinikum Düsseldorf, Düsseldorf

47051

CRC Coagulation Research Center GmbH, Duisburg/Altstadt

50134

AOU Careggi, Florence

52621

Sheba Medical Center, Tel Litwinsky

69437

Hospital Edouard Herriot, Lyon

94275

C.R.T.H. Hopital de Bicentre (Hemophilie), Le Kremlin-Bicentre

610027

"FGU Kirov Research Institute of Haemotology and Blood Trans)", Kirov

Unknown

AKH Wien (Paediatrics), Vienna

L8N3Z5

McMaster Children's Hospital, Hamilton

625 00

Fakultni nemocnice Brno, Brno

708 52

Fakultni nemocnice Ostrava, Ostrava

150 06

Fakultni nemocnice Motole, Prague

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CSL Behring

INDUSTRY